Lymphotoxin α revisited: General features and implications in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 13, Issue 4, 2011, Pages

  Calmon Hamaty, Flavia ^a   Combe, Bernard ^a,b,c   Hahne, Michael ^a,c   Morel, Jacques ^a,b,c  

^a INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN BINDING; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; TH1 CELL; TH17 CELL; TREATMENT FAILURE; TREATMENT OUTCOME; ANIMAL; IMMUNOLOGY;

ANIMALS; ARTHRITIS, RHEUMATOID; HUMANS; LYMPHOTOXIN-ALPHA;

EID: 84856620511     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3376     Document Type: Review

References (49)

1. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990, 33(Suppl 3):305-315.
2. Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL, . on behalf of the British Society for Rheumatology Biologics Register Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011, 70:583-589. 10.1136/ard.2010.139774, 3048625, 21330639, on behalf of the British Society for Rheumatology Biologics Register.
3. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004, 350(Suppl 21):2167-2179.
4. Saxne T, Palladino MA, Heinegård D, Talal N, Wollheim FA. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988, 31(Suppl 8):1041-1045.
5. Brennan FM, Chantry D, Jackson AM, Maini RN, Feldmann M. Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun 1989, 2(Suppl):177-186.
6. Robak T, Gladalska A, Stepień H. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw 1998, 9(Suppl 2):145-154.
7. Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O'Fallon WM, Goronzy JJ, Weyand CM. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001, 167(Suppl 2):1072-1080.
8. Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?. Ann Rheum Dis 2004, 63(Suppl 10):1344-1346. 1754777, 15033655.
9. Gudbrandsdottir S, Bliddal H, Petri A, Terslev L, Danneskiold-Samsoe B, Bjørnhart B, Bendtzen K, Müller K. Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis. Scand J Rheumatol 2004, 33(Suppl 6):385-388.
10. Laivoranta-Nyman S, Möttönen T, Hannonen P, Korpela M, Kautiainen H, Leirisalo-Repo M, Julkunen H, Luukkainen R, Hakala M, Vuori K, Laine AP, Toivanen A, Ilonen J, . FIN-RACo Trial Group Association of tumour necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritis. Clin Exp Rheumatol 2006, 24(Suppl 6):636-642. FIN-RACo Trial Group.
11. Williams TW, Granger GA. Lymphocyte in vitro cytotoxicity: lymphotoxins of several mammalian species. Nature 1968, 219(Suppl 5158):1076-1077.
12. Aggarwal BB, Moffat B, Harkins RN. Human lymphotoxin. Production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem 1984, 259(Suppl 1):686-691.
13. Aggarwal BB, Henzel WJ, Moffat B, Kohr WJ, Harkins RN. Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line. J Biol Chem 1985, 260(Suppl 4):2334-2344.
14. Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV, Harkins RN. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem 1985, 260(Suppl 4):2345-2354.
15. Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, Kohr WJ, Aggarwal BB, Goeddel DV. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984, 312(Suppl 5996):724-729.
16. Aggarwal BB, Eessalu TE, Hass PE. Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature 1985, 318(Suppl 6047):665-667.
17. Gommerman JL, Browning JL. Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol 2003, 3(Suppl 8):642-655.
18. Ware CF. Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 2005, 23:787-819. 10.1146/annurev.immunol.23.021704.115719, 15771586.
19. Medvedev AE, Espevik T, Ranges G, Sundan A. Distinct roles of the two tumor necrosis factor (TNF) receptors in modulating TNF and lymphotoxin alpha effects. J Biol Chem 1996, 271(Suppl 16):9778-9784.
20. Browning JL, Dougas I, Ngam-ek A, Bourdon PR, Ehrenfels BN, Miatkowski K, Zafari M, Yampaglia AM, Lawton P, Meier W, Benjamin CP, Hession C. Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors. J Immunol 1995, 154(Suppl 1):33-46.
21. Crowe PD, VanArsdale TL, Walter BN, Ware CF, Hession C, Ehrenfels B, Browning JL, Din WS, Goodwin RG, Smith CA. A lymphotoxin-beta-specific receptor. Science 1994, 264(Suppl 5159):707-710.
22. Williams-Abbott L, Walter BN, Cheung TC, Goh CR, Porter AG, Ware CF. The lymphotoxin-alpha (LTalpha) subunit is essential for the assembly, but not for the receptor specificity, of the membrane-anchored LTalpha1beta2 heterotrimeric ligand. J Biol Chem 1997, 272(Suppl 31):19451-19456.
23. Mauri DN, Ebner R, Montgomery RI, Kochel KD, Cheung TC, Yu GL, Ruben S, Murphy M, Eisenberg RJ, Cohen GH, Spear PG, Ware CF. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998, 8(Suppl 1):21-30.
24. Kuprash DV, Alimzhanov MB, Tumanov AV, Grivennikov SI, Shakhov AN, Drutskaya LN, Marino MW, Turetskaya RL, Anderson AO, Rajewsky K, Pfeffer K, Nedospasov SA. Redundancy in tumor necrosis factor (TNF) and lymphotoxin (LT) signaling in vivo: mice with inactivation of the entire TNF/LT locus versus single-knockout mice. Mol Cell Biol 2002, 22(Suppl 24):8626-8634. 139867, 12446781.
25. Fu YX, Chaplin DD. Development and maturation of secondary lymphoid tissues. Annu Rev Immunol 1999, 17:399-433. 10.1146/annurev.immunol.17.1.399, 10358764.
26. Neumann B, Luz A, Pfeffer K, Holzmann B. Defective Peyer's patch organogenesis in mice lacking the 55-kD receptor for tumor necrosis factor. J Exp Med 1996, 184(Suppl 1):259-264. 2192684, 8691140.
27. Hultgren O, Eugster HP, Sedgwick JD, Körner H, Tarkowski A. TNF/lymphotoxin-alpha double-mutant mice resist septic arthritis but display increased mortality in response to Staphylococcus aureus. J Immunol 1998, 161(Suppl 11):5937-5942.
28. Roach DR, Briscoe H, Saunders B, France MP, Riminton S, Britton WJ. Secreted lymphotoxin-alpha is essential for the control of an intracellular bacterial infection. J Exp Med 2001, 193(Suppl 2):239-246. 2193339, 11208864.
29. Ehlers S, Hölscher C, Scheu S, Tertilt C, Hehlgans T, Suwinski J, Endres R, Pfeffer K. The lymphotoxin beta receptor is critically involved in controlling infections with the intracellular pathogens Mycobacterium tuberculosis and Listeria monocytogenes. J Immunol 2003, 170(Suppl 10):5210-5218.
30. Engwerda CR, Mynott TL, Sawhney S, De Souza JB, Bickle QD, Kaye PM. Locally up-regulated lymphotoxin alpha, not systemic tumor necrosis factor alpha, is the principle mediator of murine cerebral malaria. J Exp Med 2002, 195(Suppl 10):1371-1377. 2193758, 12021316.
31. Engwerda CR, Ato M, Stäger S, Alexander CE, Stanley AC, Kaye PM. Distinct roles for lymphotoxin-alpha and tumor necrosis factor in the control of Leishmania donovani infection. Am J Pathol 2004, 165(Suppl 6):2123-2133. 1618729, 15579454.
32. Liepinsh DJ, Grivennikov SI, Klarmann KD, Lagarkova MA, Drutskaya MS, Lockett SJ, Tessarollo L, McAuliffe M, Keller JR, Kuprash DV, Nedospasov SA. Novel lymphotoxin alpha (LTalpha) knockout mice with unperturbed tumor necrosis factor expression: reassessing LTalpha biological functions. Mol Cell Biol 2006, 26(Suppl 11):4214-4225. 1489085, 16705172.
33. Picarella DE, Kratz A, Li CB, Ruddle NH, Flavell RA. Insulitis in transgenic mice expressing tumor necrosis factor beta (lymphotoxin) in the pancreas. Proc Natl Acad Sci USA 1992, 89(Suppl 21):10036-10040. 50272, 1279667.
34. Sacca R, Cuff CA, Lesslauer W, Ruddle NH. Differential activities of secreted lymphotoxin-alpha3 and membrane lymphotoxin-alpha1beta2 in lymphotoxin-induced inflammation: critical role of TNF receptor 1 signaling. J Immunol 1998, 160(Suppl 1):485-491.
35. Powell MB, Mitchell D, Lederman J, Buckmeier J, Zamvil SS, Graham M, Ruddle NH, Steinman L. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol 1990, 2(Suppl 6):539-544.
36. Suen WE, Bergman CM, Hjelmström P, Ruddle NH. A critical role for lymphotoxin in experimental allergic encephalomyelitis. J Exp Med 1997, 186(Suppl 8):1233-1240. 2199100, 9334362.
37. Pober JS, Lapierre LA, Stolpen AH, Brock TA, Springer TA, Fiers W, Bevilacqua MP, Mendrick DL, Gimbrone MA. Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species. J Immunol 1987, 138(Suppl 10):3319-3324.
38. Kratz A, Campos-Neto A, Hanson MS, Ruddle NH. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J Exp Med 1996, 183(Suppl 4):1461-1472. 2192477, 8666904.
39. Cuff CA, Schwartz J, Bergman CM, Russell KS, Bender JR, Ruddle NH. Lymphotoxin alpha3 induces chemokines and adhesion molecules: insight into the role of LT alpha in inflammation and lymphoid organ development. J Immunol 1998, 161(Suppl 12):6853-6860.
40. Mounzer RH, Svendsen OS, Baluk P, Bergman CM, Padera TP, Wiig H, Jain RK, McDonald DM, Ruddle NH. Lymphotoxin-alpha contributes to lymphangiogenesis. Blood 2010, 116(Suppl 12):2173-2182.
41. Iizuka K, Chaplin DD, Wang Y, Wu Q, Pegg LE, Yokoyama WM, Fu YX. Requirement for membrane lymphotoxin in natural killer cell development. Proc Natl Acad Sci USA 1999, 96(Suppl 11):6336-6340. 26882, 10339588.
42. Wu Q, Sun Y, Wang J, Lin X, Wang Y, Pegg LE, Fütterer A, Pfeffer K, Fu YX. Signal via lymphotoxin-beta R on bone marrow stromal cells is required for an early checkpoint of NK cell development. J Immunol 2001, 166(Suppl 3):1684-1689.
43. Smyth MJ, Johnstone RW, Cretney E, Haynes NM, Sedgwick JD, Korner H, Poulton LD, Baxter AG. Multiple deficiencies underlie NK cell inactivity in lymphotoxin-alpha gene-targeted mice. J Immunol 1999, 163(Suppl 3):1350-1353.
44. Ito D, Back TC, Shakhov AN, Wiltrout RH, Nedospasov SA. Mice with a targeted mutation in lymphotoxin-alpha exhibit enhanced tumor growth and metastasis: impaired NK cell development and recruitment. J Immunol 1999, 163(Suppl 5):2809-2815.
45. Markey KA, Burman AC, Banovic T, Kuns RD, Raffelt NC, Rowe V, Olver SD, Don AL, Morris ES, Pettit AR, Wilson YA, Robb RJ, Randall LM, Korner H, Engwerda CR, Clouston AD, Macdonald KP, Hill GR. Soluble lymphotoxin is an important effector molecule in GVHD and GVL. Blood 2010, 115(Suppl 1):122-132.
46. O'Rourke KP, O'Donoghue G, Adams C, Mulcahy H, Molloy C, Silke C, Molloy M, Shanahan F, O'Gara F. High levels of Lymphotoxin-Beta (LT-Beta) gene expression in rheumatoid arthritis synovium: clinical and cytokine correlations. Rheumatol Int 2008, 28(Suppl 10):979-986.
47. Chiang EY, Kolumam GA, Yu X, Francesco M, Ivelja S, Peng I, Gribling P, Shu J, Lee WP, Refi no CJ, Balazs M, Paler-Martinez A, Nguyen A, Young J, Barck KH, Carano RA, Ferrando R, Diehl L, Chatterjea D, Grogan JL. Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 2009, 15(Suppl 7):766-773.
48. Calmon-Hamaty F, Combe B, Hahne M, Morel J. Lymphotoxin α stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts. Cytokine 2011, 53(Suppl 2):207-214.
49. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007, 7(Suppl 6):429-442.